mfn-cus-2022 | Nanologica

Nanologica Expands Management Team for Increased Focus on Chromatography

10 August, 2022

Nanologica AB (publ) has expanded its management team with Katarina Alenäs, SVP Chromatography, as part of intensifying the company’s efforts within preparative chromatography. Katarina Alenäs took up her position as SVP Chromatograhy at Nanologica in the beginning of March, and most recently came from a role as Business Team Manager Sweden and Finland, Country General Manager Sweden and chairman of the board of Agilent Technologies Sweden AB. Katarina has a solid background and a strong

Nanologica takes out loan of MSEK 20 within agreed credit facility

27 June, 2022

Nanologica AB (publ) has taken out a loan of MSEK 20 from the credit facility agreed in January with Flerie Invest AB. The loan is taken out to cover the company's temporary financial needs pending expected cash flows from the operations in preparative chromatography. After this loan, the credit facility has been used in full. Parts of the proceeds will be used to repay a loan from a private financier of MSEK 10 that expires

Bulletin from the Annual General Meeting of Nanologica AB (publ)

2 June, 2022

Today June 2nd, 2022, Nanologica AB (publ) held its annual general meeting for the financial year 2021, where the following resolutions were passed. Adoption of income statement and balance sheet for the financial year 2021 and disposition of result The annual general meeting adopted the income statement and balance sheet for the company and for the group in accordance with the presented accounting documents, and resolved, in accordance with the board's proposal, that the accumulated

Proposal for New Stock Option Program Withdrawn

31 May, 2022

The board of directors of Nanologica AB (publ) has decided to withdraw the proposal for a new stock option program for management and employees that was presented in the notice to Nanologica's Annual General Meeting on June 2, 2022. The board of directors has decided to withdraw the proposal to await the outcome of the stock option programs that expire on July 1 this year. Depending on the outcome, a new stock option program may

Nanologica’s Interim Report Jan-Mar 2022

29 April, 2022

PERIOD IN BRIEF FINANCIAL SUMMARY Net sales for the first quarter amounted to TSEK 270 (5,622) The operating result amounted to TSEK -15,592 (-6,768) Result after tax amounted to TSEK -15,915 (-7,845) Earnings per share before and after dilution were SEK -0.57 (-0.28) Cash and cash equivalents amounted to TSEK 3,969 (57,069) as per March 31, 2022 SIGNIFICANT EVENTS IN THE FIRST QUARTER In January, a credit facility of up to MSEK 50 was signed

Nanologica takes out loan of MSEK 20 within agreed credit facility

25 April, 2022

Nanologica AB (publ) has taken out a loan of MSEK 20 from the credit facility agreed in January with Flerie Invest AB. The loan is taken out to cover the company's temporary financial needs pending expected cash flows from the operations in preparative chromatography. After this loan, MSEK 20 remains of the credit facility. For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

About us

Nanologica is a Swedish life science tools company that provides input goods to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.